Dapagliflozin preserves kidney function and reduces albuminuria in children with chronic kidney disease

Clicks: 3
ID: 324214
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #29 of 94 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce CKD progression in adults; but pediatric evidence remains limited. We evaluated dapagliflozin in children with non-diabetic CKD. METHODS: In this multicenter, randomized, open-label, endpoint-blinded controlled trial, 114 children with CKD stages 1-4 were assigned to dapagliflozin plus standard care (n=58) or standard care alone (n=56) for 4 months. Primary outcomes were changes in estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), analyzed using ANCOVA adjusted for baseline values. RESULTS: Baseline characteristics were comparable between groups. At 4 months, eGFR increased in the dapagliflozin group (+2.1 mL/min/1.73 m²) and declined in controls (-4.2 mL/min/1.73 m²), yielding a between-group difference of 6.3 mL/min/1.73 m² (95% CI 2.1-10.5; p=0.004). UACR decreased significantly with dapagliflozin versus control (between-group difference -19.8 mg/g (95% CI: -21.9 to -18.6; p=0.002). Early CKD stages showed a shift toward lower albuminuria categories. No serious adverse events occurred. CONCLUSION: Dapagliflozin was associated with short-term improvement in kidney function trajectory and reduction in albuminuria in children with CKD, with an acceptable safety profile.
Reference Key
openalex_W7197027320 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Farahnak Assadi, Elham Bidabadi, Mojgan Mazaheri, Fatemeh Ghane-Sharbaf, Toktam Faghihi, Rama Naghshizadian, Alireza Eskandarifar, Anoush Azarfar, Simin Sadeghi-Bojd, Arash Abbasi, Behnaz Bazargani, Afshin Safaei-asl, Nakysa Hooman, Hamidreza Badeli
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag177
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.